Protara Common Stock Total Equity from 2010 to 2024
| TARA Stock | USD 2.94 0.34 13.08% |
Common Stock Total Equity | First Reported 2014-12-31 | Previous Quarter 11 K | Current Value 11 K | Quarterly Volatility 4.8 K |
Check Protara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protara Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 268.5 K, Interest Expense of 1.4 M or Selling General Administrative of 15.3 M, as well as many indicators such as Price To Sales Ratio of 8.65, Dividend Yield of 0.0 or PTB Ratio of 0.3. Protara financial statements analysis is a perfect complement when working with Protara Therapeutics Valuation or Volatility modules.
Protara | Common Stock Total Equity |
Latest Protara Therapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Protara Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Protara Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Protara Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 14,456 | |
| Geometric Mean | 14,152 | |
| Coefficient Of Variation | 20.66 | |
| Mean Deviation | 2,653 | |
| Median | 16,000 | |
| Standard Deviation | 2,986 | |
| Sample Variance | 8.9M | |
| Range | 9.1K | |
| R-Value | (0.67) | |
| Mean Square Error | 5.2M | |
| R-Squared | 0.45 | |
| Significance | 0.01 | |
| Slope | (450.24) | |
| Total Sum of Squares | 124.8M |
Protara Common Stock Total Equity History
About Protara Therapeutics Financial Statements
Protara Therapeutics stakeholders use historical fundamental indicators, such as Protara Therapeutics' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Protara Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Protara Therapeutics' assets and liabilities are reflected in the revenues and expenses on Protara Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Protara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 9.9 K | 12.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out the analysis of Protara Therapeutics Correlation against competitors. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.